Trial Profile
Safety and efficacy of bevacizumab and/or systemic chemotherapy in metastatic colorectal cancer (mCRC) patients with peritoneal disease in the Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) database
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 21 Aug 2020
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Antineoplastics
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 17 Aug 2020 Results developing a simulation model to estimate progression-free survival (PFS) and overall survival for first-line doublet chemotherapy with or without bevacizumab for specific subgroups of metastatic colorectal cancer (mCRC) patients based on TRACC registry, published in the PharmacoEconomics
- 18 Dec 2015 New trial record